logo-loader
viewSilence Therapeutics PLC

Drug at centre of Silence Therapeutics legal action added to UK Early Access to Medicines Scheme

“With regards to IP and patents, Silence will vigorously enforce its patent estate where third parties are considered to be infringing the company's patent rights," said Silence chief executive, Dr David Horn Solomon

judge's gave ad scales
The case goes to court in December with a ruling expected in early 2019

A drug that is the focus of legal action by Silence Therapeutics PLC (LON:SLN) has been granted limited approval here in the UK.

Patisiran, a new-breed of RNAi medicine developed by American biotech Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), will join the Early Access to Medicines Scheme.

READ: Silence Therapeutics names experienced biotech boss as its new chief executive officer

This means Britons with a rare neuro-degenerative disease can receive the treatment before it gains EU marketing authorisation.

Patisiran is at the centre of a court case, set for trial in December, with Silence Therapeutics claiming it infringes intellectual property (IP) the UK life sciences group developed and owns.

“With regards to IP and patents, Silence will vigorously enforce its patent estate where third parties are considered to be infringing the company's patent rights," said chief executive, Dr David Horn Solomon.

Quick facts: Silence Therapeutics PLC

Price: 505 GBX

AIM:SLN
Market: AIM
Market Cap: £395.77 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Silence Therapeutics CEO talks recent RNAi deals and updates on critical...

Silence Therapeutics PLC's (LON:SLN) David Solomon discusses with Proactive London's Andrew Scott the recent deal between Novartis and The Medicines Company for its asset - the RNAi project inclisiran. Solomon also updates on their lead candidate, SLN124, which is being developed to treat...

2 weeks, 4 days ago

RNS

Additional Listing

2 weeks, 5 days ago

Additional Listing

3 weeks, 3 days ago

Holding(s) in Company

on 13/11/19

Additional Listing

on 30/10/19

Additional Listing

on 25/10/19

Holding(s) in Company

on 14/10/19

Holdings in Company

on 7/10/19

2 min read